Urology News and Research RSS Feed - Urology News and Research

Urology is the field of medicine that focuses on the urinary tracts of males and females, and on the reproductive system of males. In men, the urinary system overlaps with the reproductive system, and in women the urinary tract opens into the vulva. In both sexes, the urinary and reproductive tracts are close together, and disorders of one often affect the other. The organs covered by urology include the kidneys, ureters, urinary bladder, urethra, and the male reproductive organs (testes, epididymis, vas deferens, seminal vesicles, prostate and penis).
Further Reading
Allergan enters into agreement to acquire Oculeve

Allergan enters into agreement to acquire Oculeve

Allergan plc, a leading global pharmaceutical company, and Oculeve, a development-stage medical device company focused on developing novel treatments for dry eye disease, today announced that they have entered into an agreement under which Allergan will acquire Oculeve in an all-cash transaction. [More]
Roswell Park, Lakeshore Cancer Center partner to improve access to cancer care for Nigerians

Roswell Park, Lakeshore Cancer Center partner to improve access to cancer care for Nigerians

America's oldest cancer center and one of the world's newest oncology centers are partnering to improve access to cancer prevention, screening and care for the people of Nigeria. Roswell Park Cancer Institute and Lakeshore Cancer Center have announced an affiliation that will see Roswell Park faculty providing clinical consultations to assist LCC oncologists, who will also have access to both training at RPCI and continuing professional education seminars they can participate in remotely. [More]
Telesta submits Biologics License Application for MCNA to FDA

Telesta submits Biologics License Application for MCNA to FDA

Telesta Therapeutics Inc. announced today that it has submitted electronically, through its U.S. agent, a Biologics License Application (BLA) to the United States Food and Drug Administration for MCNA. MCNA is Telesta's novel biologic immunotherapeutic for the treatment of high-risk non-muscle invasive bladder cancer patients who have failed first-line BCG therapy. [More]
Drugs used against impotence does not increase risk of malignant melanoma

Drugs used against impotence does not increase risk of malignant melanoma

Using drugs for impotence does not increase the risk of malignant melanoma, researchers from Umeå University in Sweden conclude in a publication in JAMA, a top US medical journal. These results contradict previous research indicating such an association. [More]
Bariatric surgery can significantly reduce urinary incontinence

Bariatric surgery can significantly reduce urinary incontinence

For severely obese people, bariatric surgery may have a benefit besides dramatic weight loss: it can also substantially reduce urinary incontinence. [More]
The Miriam Hospital offers new surgical treatment for benign prostatic hyperplasia

The Miriam Hospital offers new surgical treatment for benign prostatic hyperplasia

The Minimally Invasive Urology Institute at The Miriam Hospital is offering UroLift as one of the newest surgical treatments available for men with benign prostatic hyperplasia (BPH), an enlarged prostate condition. [More]
International study provides evidence of clear link between smoking and risk of prostate cancer

International study provides evidence of clear link between smoking and risk of prostate cancer

Smoking is a known risk factor for the development of various forms of cancer. However, when it comes to the link between smoking and prostate cancer, the findings of previous studies have been contradictory. Now, for the first time, an international study led by MedUni Vienna and Basle University Hospital, has provided evidence of a clear link. [More]
Study shows 28% decline in prostate cancer diagnoses following USPSTF recommendation against PSA testing

Study shows 28% decline in prostate cancer diagnoses following USPSTF recommendation against PSA testing

A new study led by Vanderbilt University Medical Center investigators found new diagnoses of prostate cancer in the U.S. declined 28 percent in the year following the draft recommendation from the United States Preventive Services Task Force against routine PSA screening for men. [More]
Simple test could help identify genetically inherited risk for prostate cancer

Simple test could help identify genetically inherited risk for prostate cancer

Men with an elevated, genetically inherited risk for prostate cancer could be routinely identified with a simple blood or urine test, scientists at UC San Francisco and Kaiser Permanente Northern California have concluded, potentially paving the way to better or earlier diagnosis. [More]
Allergan agrees to acquire KYTHERA Biopharmaceuticals for $2.1 billion

Allergan agrees to acquire KYTHERA Biopharmaceuticals for $2.1 billion

Allergan plc, a leading global pharmaceutical company, and KYTHERA Biopharmaceuticals, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market, today announced that they have entered into a definitive agreement under which Allergan has agreed to acquire KYTHERA in a cash and equity transaction valued at $75 per KYTHERA share, or approximately $2.1 billion. [More]
Samadi Robotics Foundation gets donation to find cure for prostate cancer

Samadi Robotics Foundation gets donation to find cure for prostate cancer

World renowned robotic prostate cancer surgeon, Dr. David B. Samadi, was awarded the Peter Latos Prostate Cancer Foundation Award last Thursday at the Foundation's 2nd Annual Gala where he was honored in recognition of his faithful service for the treatment, prevention and innovation in the fight against prostate cancer. [More]
Study highlights discovery of genetic variants linked to mucinous ovarian carcinomas

Study highlights discovery of genetic variants linked to mucinous ovarian carcinomas

New research by an international team including Keck Medicine of USC scientists is bringing the origins of ovarian cancer into sharper focus. [More]
Actavis adopts Allergan as its new global name

Actavis adopts Allergan as its new global name

Actavis plc announced that the company has adopted Allergan plc as its new global name and will begin trading today under a new symbol — AGN — after ringing The Opening Bell at the New York Stock Exchange. [More]
Taiho, Servier sign exclusive license agreement to develop and commercialize TAS-102 drug

Taiho, Servier sign exclusive license agreement to develop and commercialize TAS-102 drug

Taiho Pharmaceutical Co., Ltd.(Japan) and Servier (France) announced on June 15 that they have entered into an exclusive license agreement on June 12, 2015 for the development and commercialization of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride) in Europe and other countries. [More]
Men who use finasteride to treat benign prostate enlargement experience worsening ED

Men who use finasteride to treat benign prostate enlargement experience worsening ED

Men with benign prostate enlargement who used finasteride (also known as proscar and propecia) to treat their condition, experienced worsening erectile dysfunction (ED) that did not resolve with continued treatment. In addition, they experienced a reduction in their testosterone levels leading to hypogonadism (little to no production of sex hormones). [More]
Findings underscore the value of emotional, informational support for prostate cancer patients

Findings underscore the value of emotional, informational support for prostate cancer patients

A study led by the University at Buffalo and Roswell Park Cancer Institute has identified beliefs and personality traits that are associated with higher levels of distress in newly diagnosed prostate cancer patients. [More]
Only 50% of men can remember their last medical check-up, shows new national survey

Only 50% of men can remember their last medical check-up, shows new national survey

A new national survey about men and their cars, commissioned by Orlando Health, found that more than 80 percent of men could remember the make and model of their first car, but only about half could remember the last time they went to the doctor for a check-up. [More]
Kravis Children's Hospital named one of country's top children's hospitals in pediatric specialties

Kravis Children's Hospital named one of country's top children's hospitals in pediatric specialties

The Kravis Children's Hospital at Mount Sinai ranked again among the country's top children's hospitals in pediatric specialties, according to the newly issued U.S. News & World Report's "Best Children's Hospitals" guidebook for 2015-2016. [More]
Janssen begins rolling submission of daratumumab BLA to FDA for treatment of patients with multiple myeloma

Janssen begins rolling submission of daratumumab BLA to FDA for treatment of patients with multiple myeloma

Janssen Research & Development, LLC has initiated the rolling submission of its Biologic License Application (BLA) for daratumumab to the U.S. Food and Drug Administration (FDA) for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double refractory to a PI and an IMiD. [More]
Actavis receives FDA approval to market NATRELLE INSPIRA round gel-filled textured breast implants

Actavis receives FDA approval to market NATRELLE INSPIRA round gel-filled textured breast implants

Actavis plc, which recently completed the acquisition of Allergan, Inc., today announced that the company has received approval from the U.S. Food and Drug Administration to market NATRELLE INSPIRA round gel-filled textured breast implants, offering women undergoing reconstruction, augmentation or revision surgery another breast shaping option for a customized result. [More]
Advertisement
Advertisement